Aurobindo Pharma Ltd
Aurobindo Pharma Ltd (AUROPHARMA) last traded at ₹1,614, a market capitalisation of ₹92,872 crore, on a P/E of 24.5. Over the past 52 weeks the stock has ranged between ₹1,016 and ₹1,682. Aurobindo Pharma Ltd last reported results for the quarter ended Jun 2026, with sales of ₹9,150 crore and net profit of ₹1,032 crore. The next scheduled event is an analyst meet on 1 Sept 2026. Figures are as of 25 Aug 2026 and are not real time.
Aurobindo Pharma Ltd share price and key metrics
Metrics as of 25 Aug 2026. Not real time.
Aurobindo Pharma Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹9,150 cr, up 16.3% from ₹7,868 cr a year earlier. Net profit was ₹1,032 cr, up 25.2% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 7,796 | 7,979 | 8,382 | 7,868 | 8,286 | 8,646 | 8,853 | 9,150 |
| Expenses | 6,230 | 6,401 | 6,622 | 6,265 | 6,608 | 6,873 | 7,103 | 7,271 |
| Operating profit | 1,566 | 1,578 | 1,760 | 1,603 | 1,678 | 1,773 | 1,750 | 1,880 |
| OPM % | 20% | 20% | 21% | 20% | 20% | 21% | 20% | 21% |
| Other income | 136 | 159 | 135 | 107 | 122 | 123 | 117 | 224 |
| Interest | 113 | 118 | 115 | 98 | 95 | 93 | 98 | 102 |
| Depreciation | 382 | 419 | 444 | 406 | 429 | 465 | 479 | 487 |
| Profit before tax | 1,207 | 1,200 | 1,335 | 1,207 | 1,276 | 1,339 | 1,291 | 1,515 |
| Tax % | 32% | 30% | 32% | 32% | 34% | 32% | 29% | 32% |
| Net profit | 817 | 846 | 903 | 824 | 848 | 910 | 921 | 1,032 |
| EPS (₹) | 14.07 | 14.56 | 15.56 | 14.20 | 14.61 | 15.67 | 15.86 | 17.95 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Aurobindo Pharma Ltd annual results
| ₹ crore | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|
| Sales | 24,775 | 23,455 | 24,855 | 29,002 | 31,724 | 33,653 | 34,935 |
| Operating profit | 5,278 | 4,396 | 3,707 | 5,826 | 6,560 | 6,870 | 7,081 |
| OPM % | 21% | 19% | 15% | 20% | 21% | 20% | 20% |
| Net profit | 5,334 | 2,647 | 1,928 | 3,169 | 3,484 | 3,503 | 3,711 |
| EPS (₹) | 91.05 | 45.20 | 32.90 | 54.15 | 60.02 | 60.34 | 64.09 |
TTM is the trailing twelve months to the most recent quarter.
Aurobindo Pharma Ltd growth and returns
- 10 Years
- 9%
- 5 Years
- 6%
- 3 Years
- 11%
- TTM
- 9%
- 10 Years
- 6%
- 5 Years
- 1%
- 3 Years
- 23%
- TTM
- 11%
- 10 Years
- 7%
- 5 Years
- 18%
- 3 Years
- 25%
- 1 Year
- 51%
- 10 Years
- 14%
- 5 Years
- 10%
- 3 Years
- 11%
- Last Year
- 10%
Aurobindo Pharma Ltd shareholding pattern
Promoters held 51.88% at Jun 2026, broadly unchanged since Jun 2025. FIIs 16.38% and DIIs 25.05%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 51.82% | 51.82% | 51.82% | 51.82% | 51.82% | 51.82% | 51.82% | 51.88% |
| FIIs | 16.59% | 16.29% | 15.33% | 14.38% | 14.21% | 13.95% | 15.24% | 16.38% |
| DIIs | 25.14% | 25.21% | 26.23% | 26.93% | 27.60% | 27.66% | 25.82% | 25.05% |
| Government | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.03% | 0.05% | 0.05% |
| Public | 6.45% | 6.67% | 6.61% | 6.88% | 6.37% | 6.55% | 7.08% | 6.63% |
| No. of shareholders | 2,48,488 | 2,57,962 | 2,69,323 | 2,72,208 | 2,47,662 | 2,36,859 | 2,41,298 | 2,39,073 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Upcoming Aurobindo Pharma Ltd events
The next scheduled event is an analyst meet on 1 Sept 2026.
- Analyst meetParticipation in ASHWAMEDH – Elara India Dialogue 2026
See the full results calendar for every Indian company reporting in the next 30 days.
Aurobindo Pharma Ltd corporate filings
- Intimation of Participation in Investor/ Analyst meet held on September 1-2, 2026 in Hong KongCompany Updatelow impact
Cruxal's analysis: Aurobindo Pharma has announced its participation in investor and analyst meetings…
Read the full analysis - Intimation of Investor/ Analyst meet scheduled on September 1, 2026.Company Updatelow impact
Cruxal's analysis: Aurobindo Pharma has issued a formal intimation regarding an investor and analyst meeting…
Read the full analysis - Intimation of completion of US FDA inspection at Lannett Company LLC., a wholly owned subsidiary of Aurobindo Pharma, USA Inc.Company Updatelow impact
Cruxal's analysis: Aurobindo Pharma has announced the successful completion of a US FDA inspection at its…
Read the full analysis - Intimation of completion of US FDA inspection at Auro Peptides Limited, a subsidiary of the Company.Company Updatelow impact
Cruxal's analysis: Aurobindo Pharma has announced the successful completion of a US FDA inspection at its…
Read the full analysis - Intimation of classification of US FDA inspection at Raleigh Plant, North Carolina, owned by Aurolife LLF, a wholly owned step down subsidiary of the Company, as Voluntary Actioin Indicated (VAI).Company Updatelow impact
Cruxal's analysis: Aurobindo Pharma has announced that the US FDA has classified the inspection of its…
Read the full analysis - Intimation of participation of officials of the Company in investors / analysts meet to be held on August 19, 2026Company Updatelow impact
Cruxal's analysis: Aurobindo Pharma has announced that company officials will participate in an investor and…
Read the full analysis - Intimation of receipt of warning letter from US FDA by Unit 1 of Eugia Pharma Specialities Limited, a wholly owned subsidiary of the Company.Company Updatemedium impact
Cruxal's analysis: Aurobindo Pharma has disclosed that Unit I of its wholly owned subsidiary, Eugia Pharma…
Read the full analysis - Submission of transcript of the earning call on the unaudited financial results for the quarter ended June 30, 2026.Company Updatehigh impact
Cruxal's analysis: Aurobindo Pharma reported a strong Q1 FY27 with consolidated revenue of 9,150 crore, up…
Read the full analysis - Intimation of incorporation of a new wholly owned subsidiary.Company Updatelow impact
Cruxal's analysis: Aurobindo Pharma Limited has incorporated a new wholly owned subsidiary, 'Auropharm…
Read the full analysis - Submission of copies of notice published by the Company on August 7, 2026 in Business Standard and Nava Telangana regarding special window for re-lodgement of transfer requests of physical shares.Company Updatelow impact
Cruxal's analysis: Aurobindo Pharma has published a notice in Business Standard and Nava Telangana on August…
Read the full analysis - Submission of copies of newspaper advertisements of the financial results of the Company for the first quarter ended June 30, 2026 as published in Business Standard and Nava Telangana on ....Company Updatelow impact
Cruxal's analysis: Aurobindo Pharma Limited has released its financial results for the first quarter ended…
Read the full analysis - Intimation of participation by the officials of the Company in the Investor/Analyst Meet to be held on August 11 to 13, 2026 in Singapore & Hong KongCompany Updatelow impact
Cruxal's analysis: Aurobindo Pharma has announced that company officials will participate in investor and…
Read the full analysis - Intimation of proposal of merger of two wholly owned stepdown subsidiaries with a wholly owned subsidiary.Company Updatelow impact
Cruxal's analysis: Aurobindo Pharma Limited has received board approval for the merger of its step-down…
Read the full analysis - Submission of Press Release on financial results of the Company for the first quarter ended June 30, 2026.Company Updatehigh impact
Cruxal's analysis: Aurobindo Pharma Limited reported a strong performance for the quarter ended June 30…
Read the full analysis - Submission of investor presentation.Company Updatehigh impact
Cruxal's analysis: Aurobindo Pharma Limited reported a strong Q1FY27 performance with revenue of 9,150…
Read the full analysis - The Board of Directors of the Company at its meeting held today, August 5, 2026, has, inter alia, considered and approved: a) the standalone and consolidated Unaudited Financial Results ....Board Meetinghigh impact
Cruxal's analysis: Aurobindo Pharma reported strong consolidated financial results for the quarter ended…
Read the full analysis - Submission of copies of notice published in newspapers.Company Updatelow impact
Cruxal's analysis: Aurobindo Pharma Ltd. has submitted copies of a notice published in newspapers on…
Read the full analysis - Confirmation of dispatch of letter to the shareholders who have not registered their email ids, providing weblink for integrated Annual Report 2025-26.Company Updatelow impact
Cruxal's analysis: Aurobindo Pharma Ltd. announced on August 4, 2026, the confirmation of dispatching…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Track Aurobindo Pharma Ltd
Cruxal reads every Aurobindo Pharma Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.